Galectin Therapeutics Inc. (NASDAQ:GALT – Get Free Report) major shareholder James C. Czirr sold 21,323 shares of the company’s stock in a transaction dated Monday, April 22nd. The stock was sold at an average price of $3.06, for a total transaction of $65,248.38. Following the completion of the transaction, the insider now owns 5,925,884 shares of the company’s stock, valued at approximately $18,133,205.04. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Major shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.
Galectin Therapeutics Price Performance
GALT stock opened at $3.50 on Friday. The firm has a 50-day simple moving average of $2.54 and a 200-day simple moving average of $2.10. Galectin Therapeutics Inc. has a 52 week low of $1.28 and a 52 week high of $4.27.
Galectin Therapeutics (NASDAQ:GALT – Get Free Report) last released its earnings results on Friday, March 29th. The company reported ($0.16) EPS for the quarter. On average, analysts predict that Galectin Therapeutics Inc. will post -0.66 EPS for the current fiscal year.
Institutional Trading of Galectin Therapeutics
Analyst Upgrades and Downgrades
A number of research analysts have weighed in on the stock. StockNews.com upgraded shares of Galectin Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, April 1st. HC Wainwright reiterated a “buy” rating and issued a $11.00 price objective on shares of Galectin Therapeutics in a research report on Tuesday, April 9th.
Read Our Latest Report on GALT
About Galectin Therapeutics
Galectin Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer.
Featured Articles
- Five stocks we like better than Galectin Therapeutics
- Stock Ratings and Recommendations: Understanding Analyst Ratings
- Hasbro’s Management Made All the Right Calls This Quarter
- What Investors Need to Know to Beat the Market
- Caterpillar’s Market Reset Isn’t Over: Get Ready for Lower Prices
- How to Calculate Retirement Income: MarketBeat’s Calculator
- Power Surge: Utilities Sector’s Resilience Shines
Receive News & Ratings for Galectin Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galectin Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.